Gedatolisib (PF‐05212384), another dual PI3K/mTOR inhibitor, has shown promising preclinical activity and safety in phase I trials for solid tumors such as breast cancer [33], ovarian cancer [34], and non‐small cell lung cancer (NSCLC) [35]. This evidence concerns the gene PIK3CA and breast carcinoma.